Loading...
XKRX
004720
Market cap59mUSD
Jun 11, Last price  
4,485.00KRW
1D
0.90%
1Q
7.68%
Jan 2017
-74.00%
Name

PharmGen Science Inc

Chart & Performance

D1W1MN
XKRX:004720 chart
P/E
29.18
P/S
0.48
EPS
153.68
Div Yield, %
—
Shrs. gr., 5y
10.91%
Rev. gr., 5y
12.48%
Revenues
171.29b
+2.70%
78,559,320,00077,680,145,00048,740,944,00043,926,893,00027,911,913,08030,291,620,67038,971,052,56044,203,012,42060,405,445,20071,545,613,18079,894,496,57089,101,640,00095,137,668,55096,614,310,440109,866,066,810150,930,715,370166,778,825,650171,286,609,680
Net income
2.79b
-51.27%
-221,835,000-11,315,404,000-1,946,753,000-2,765,635,000-8,823,738,000-5,231,609,800-3,698,557,000-4,583,680,0002,067,281,0003,452,135,9304,319,900,3104,467,984,120235,995,6009,222,178,37032,465,959,37070,059,662,0405,727,238,8302,790,818,530
CFO
2.38b
-56.16%
-5,533,603,0003,823,582,000-14,702,708,000628,491,0002,893,279,980-3,975,637,310-4,204,856,380-2,016,894,3203,621,572,7407,754,655,7901,837,763,3804,215,582,0902,523,396,0002,675,611,6407,784,092,730-1,286,177,4105,438,941,4492,384,288,570

Profile

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.
URL
http://www.wooridulpharm.com/
IPO date
Jun 15, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
171,286,610
2.70%
166,778,826
10.50%
150,930,715
37.38%
Cost of revenue
139,097,314
137,560,042
120,337,927
Unusual Expense (Income)
NOPBT
32,189,295
29,218,783
30,592,788
NOPBT Margin
18.79%
17.52%
20.27%
Operating Taxes
(1,772,503)
2,265,007
19,902,113
Tax Rate
7.75%
65.05%
NOPAT
33,961,799
26,953,777
10,690,675
Net income
2,790,819
-51.27%
5,727,239
-91.83%
70,059,662
115.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(12,407)
(5,767)
BB yield
0.01%
0.00%
Debt
Debt current
38,639,536
37,431,144
39,001,393
Long-term debt
1,103,413
1,475,532
1,426,194
Deferred revenue
4
Other long-term liabilities
17,072,388
14,980,866
13,413,777
Net debt
(194,086,999)
(180,534,194)
(166,187,122)
Cash flow
Cash from operating activities
2,384,289
5,438,941
(1,286,177)
CAPEX
(918,703)
(2,265,915)
(11,956,258)
Cash from investing activities
(889,449)
3,260,040
(15,284,385)
Cash from financing activities
(483,954)
8,851,958
2,269,033
FCF
21,462,759
16,539,395
1,178,892
Balance
Cash
38,448,986
37,437,384
19,885,875
Long term investments
195,380,962
182,003,486
186,728,833
Excess cash
225,265,618
211,101,929
199,068,172
Stockholders' equity
144,788,190
139,084,030
135,332,943
Invested Capital
160,701,488
142,071,627
122,626,320
ROIC
22.43%
20.37%
8.64%
ROCE
9.56%
9.42%
10.69%
EV
Common stock shares outstanding
19,369
20,796
21,591
Price
4,090.00
-34.03%
6,200.00
-7.19%
6,680.00
-36.38%
Market cap
79,220,044
-38.56%
128,933,724
-10.60%
144,228,541
-26.14%
EV
(114,878,114)
(51,610,577)
(21,967,651)
EBITDA
36,825,192
33,465,510
33,963,918
EV/EBITDA
Interest
4,156,721
4,263,984
3,508,941
Interest/NOPBT
12.91%
14.59%
11.47%